Skip to main content
. 2016 Jun 30;7(30):47998–48010. doi: 10.18632/oncotarget.10332

Figure 3. PLK1 inhibition plus EGFR inhibition is synergistic in ER PC9 cell lines harboring T790M EGFR mutations.

Figure 3

The viability of ER PC9 cell lines treated with volasertib and/or erlotinib for 72 h was assessed with the CellTiter-Glo assay. The CI of the two drugs was calculated using the Calcusyn software program. CI depicts synergism (CI < 1), additive effect (CI = 1), and antagonism (CI > 1).